NCT05465161 STING MARK Universal Fiducial Marker System
| NCT ID | NCT05465161 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-02-28 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-02-28 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Currently available fiducial marker and fiducial insertion strategies are rudimentary, imprecise, not compatible with multiple insertion catheters/needles and are overall unreliable. STING-MARK device is the first universal, fully detachable and non-premounted radiopaque fiducial device system. Allowing biopsy prior to insertion, STING-MARK is easily and reliably delivered through-the-needle to the tumor, in order to accurately pinpoint its location for image-guided therapies. This study aims at establishing proof of concept for STING-MARK, by demonstrating its usability, reproducibility, radio-opacity and retention in a variety of clinically-relevant ex vivo organ samples.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing surgical resection of solid organs * Recipients of solid organ transplantation Exclusion Criteria: * None
Contact & Investigator
Moishe Liberman, MD
PRINCIPAL INVESTIGATOR
CHUM
Frequently Asked Questions
Who can join the NCT05465161 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05465161 currently recruiting?
Yes, NCT05465161 is actively recruiting participants. Contact the research team at moishe.liberman@umontreal.ca for enrollment information.
Where is the NCT05465161 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT05465161 clinical trial?
NCT05465161 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM). The principal investigator is Moishe Liberman, MD at CHUM. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.